Search results
Alexion is a global biopharmaceutical company that develops life-changing therapies for people living with rare disorders, such as hemophagocytic lymphohistiocytosis (HPP), myasthenia gravis (MG), and lysosomal acid lipase deficiency (LALD). Learn about their work, their stories, their news, and their career opportunities.
- Career Opportunities
Life at Alexion: Being Part Of AstraZeneca. In July 2021,...
- Medicines
Alexion delivers therapies for people living with rare and...
- Contact Us
Contact Us. In order to direct your inquiry to the correct...
- About Us
Our culture is rooted in integrity, inclusiveness, and our...
- Our Inspiration
Living With Rare Diseases. Rare diseases can be devastating...
- Our Research
Alexion is committed to collaborating with researchers on...
- Our Commitment
Applicants own and control the activity and any related...
- Career Opportunities
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases . Its products include eculizumab (Soliris) and ravulizumab (Ultomiris), both used to treat the rare disorders of atypical hemolytic uremic ...
- 1992; 31 years ago
- Boston, Massachusetts, U.S.
- 2,525 (2020)
- US$6.069 billion (2020)
Jul 28, 2023 · Alexion, AstraZeneca Rare Disease, announces a purchase and licence agreement for a portfolio of preclinical gene therapy programmes and enabling technologies from Pfizer. The agreement furthers Alexion's ambition to transform patient outcomes with genomic medicine and provides synergistic opportunities across AstraZeneca's portfolio.
Oct 3, 2022 · Alexion, AstraZeneca Rare Disease, has entered a definitive agreement to buy LogicBio, a genomic medicine company, for $2.07 per share. The deal aims to combine Alexion's and AstraZeneca's research in gene editing and AAV capsid development for rare and serious diseases.
People also ask
What makes Alexion unique?
Where is Alexion Pharmaceuticals located?
Is Alexion a Pfizer company?
What is Alexion & AstraZeneca rare disease?
Jul 21, 2021 · AstraZeneca completed the acquisition of Alexion Pharmaceuticals, Inc. for $13.3bn in cash and 236,321,411 new AstraZeneca shares. The deal marks the Company's entry into medicines for rare diseases and the beginning of a new chapter for AstraZeneca. The closing of the transaction was effective on 22 July 2021 and the new AstraZeneca shares will be listed on the London Stock Exchange.